Cargando…
Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin
Nephrotoxicity is a dose limiting side effect associated with the use of cisplatin in the treatment of solid tumors. The degree of nephrotoxicity is dictated by the selective accumulation of cisplatin in renal tubule cells due to: (1) uptake by organic cation transporter 2 (OCT2) and copper transpor...
Autores principales: | Chang, Cara, Hu, Yichun, Hogan, Susan L., Mercke, Nickie, Gomez, Madeleine, O’Bryant, Cindy, Bowles, Daniel W., George, Blessy, Wen, Xia, Aleksunes, Lauren M., Joy, Melanie S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5535826/ https://www.ncbi.nlm.nih.gov/pubmed/28640195 http://dx.doi.org/10.3390/ijms18071333 |
Ejemplares similares
-
Time-dependent changes in kidney injury biomarkers in patients receiving multiple cycles of cisplatin chemotherapy
por: George, Blessy, et al.
Publicado: (2020) -
In Vitro Inhibition of Renal OCT2 and MATE1 Secretion by Antiemetic Drugs
por: George, Blessy, et al.
Publicado: (2021) -
The Excretion of Cisplatin after Hyperthermic Intrathoracic Chemotherapy
por: Larisch, Christopher, et al.
Publicado: (2023) -
Urinary pseudouridine excretion in myelomatosis.
por: Sørensen, S. H., et al.
Publicado: (1985) -
Pharmacogenomics of Cisplatin Sensitivity in Non-small Cell Lung Cancer
por: Rose, Maimon C., et al.
Publicado: (2014)